Clinical Trial

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-14; most recent amendment 2025-08-07.
Trial Details
NCT Number NCT06690970
Lead Sponsor Tianjin Medical University
Collaborators: Tianjin Medical University General Hospital
Conditions PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis, FAP
Enrollment 500 participants
Start Date 2020-09-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-11